Radformation's OptiPlan VMAT Planning Automation Clears FDA

FDA clearance expands automated planning access

Radformation has secured FDA 510(k) clearance (K261718) for OptiPlan, an automated volumetric modulated arc therapy (VMAT) planning module integrated within its EZFluence platform. The September 2026 clearance enables clinical deployment across the United States following earlier launches in European and Canadian markets.

OptiPlan addresses a persistent challenge in radiation oncology: the time-intensive nature of treatment plan optimization. The module automates repetitive aspects of VMAT planning while preserving clinician control over clinical decision-making, according to Jayne Churness, Director of Product Management at Radformation.

How the automation works

The system operates by analyzing patient anatomy alongside clinical priorities established through ClearCheck templates. Unlike machine learning-based planning tools, OptiPlan generates treatment plans without requiring model training or site-specific commissioning—a distinction that potentially accelerates implementation timelines.

Treatment planners can evaluate multiple plan configurations simultaneously, comparing how different optimization strategies balance target coverage against organ-at-risk sparing. This side-by-side comparison workflow allows clinicians to select the approach that best aligns with individual patient objectives before finalizing treatment parameters.

Why it matters

Radiation therapy departments face mounting pressure to maintain plan quality while managing increasing patient volumes. Automation tools that reduce planning time without sacrificing clinical judgment could help address workforce capacity constraints. The ability to deploy OptiPlan without extensive model training may lower barriers to adoption compared to AI-based alternatives that require substantial upfront data preparation and validation work.

Availability and integration

OptiPlan functions as an optional module within the broader EZFluence platform rather than a standalone product. Radformation notes that availability varies by market and remains subject to regional regulatory approvals beyond the recent U.S. clearance.

The company developed OptiPlan in response to direct feedback from treatment planning users seeking efficiency improvements that don't compromise their role in clinical decision-making. By handling routine optimization tasks, the module aims to redirect planner attention toward complex cases and nuanced clinical judgments where human expertise provides the greatest value.

Details on OptiPlan were first reported by Automation Watch and are available through Radformation's website.